Arvinas Inc
Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC ® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC ® targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC ® protein degraders against validated and “undruggable” targets, the company has two clinical-stage programs: ARV-110 for the treatment of men with metastatic castrate-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer.
Holds 16.1x more cash than debt — a strong balance sheet.
Current Price
$10.51
+6.16%Arvinas Inc (ARVN) Social Sentiment
ARVN Social Sentiment Analysis
Social media sentiment analysis for Arvinas Inc (ARVN). Track bullish and bearish sentiment, mention volume, and BuzzScore trends from StockTwits and Reddit. Social sentiment provides a crowd-sourced view of investor confidence in ARVN.
Current stock price: $10.51. Market cap: $675.00M. This page displays sentiment timelines, bullish vs bearish ratios, total mention counts, peak BuzzScore data, and source breakdowns for ARVN. The sentiment data is updated regularly to reflect the latest social media activity.
Social sentiment is one of many signals to consider when evaluating a stock. High bullish sentiment combined with strong fundamentals may reinforce a buy thesis. Use GoodMoat's sentiment tracking alongside quality analysis, financial data, and valuation models to make well-informed investment decisions about Arvinas Inc.